9.36

6.40% -0.64

Palatin Technologies Inc. (PTN)

Overview News Price History Option Chain Discussions Forecast Stock Split

Palatin Technologies Inc. stock is traded at $9.36, with a volume of 12,253. It is down -6.40% in the last 24 hours and up +5.76% over the past month. Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders. In addition, the company develops natriuretic peptide receptor systems comprising PL3994, a natriuretic peptide receptor-A agonist, which has completed Phase I clinical study for the treatment of cardiovascular indications; and PL-5028, a dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.

Previous Close:

$10.00

Open:

$10.27

24h Volume:

12,253

Relative Volume:

0.66

Market Cap:

$16.65M

Revenue:

$12.88M

Net Income/Loss:

$-6.25M

P/E Ratio:

-6.8481

EPS:

-1.3668

Net Cash Flow:

$-14.98M

1W Performance:

+20.46%

1M Performance:

+5.76%

6M Performance:

-46.18%

1Y Performance:

+9,847%

1-Day Range:

$8.8091

$10.27

1-Week Range:

$7.2701

$10.93

52-Week Range:

$7.21

$31.00

Palatin Technologies Inc. Stock (PTN) Company Profile

Name

Palatin Technologies Inc.

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

609-495-2200

Address

Cedar Brook Corporate Center, 4B Cedar Brook Drive, Cranbury, NJ

Employee

Twitter

@PalatinTech

Next Earnings Date

2026-08-12

Latest SEC Filings

PTN's Discussions on Twitter

Compare PTN vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PTN Palatin Technologies Inc.	9.36	16.85M	12.88M	-6.25M	-14.98M	-1.3668
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Palatin Technologies Inc. Stock (PTN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-12-25	Initiated	Laidlaw	Buy
Dec-03-25	Initiated	Alliance Global Partners	Buy
Jun-05-15	Reiterated	Canaccord Genuity	Buy
Jan-12-15	Reiterated	ROTH Capital	Buy
May-23-12	Initiated	Noble Financial	Buy
Jan-23-07	Initiated	Next Generation	Buy

View All

Palatin Technologies Inc. Stock (PTN) Latest News

Aug 14, 2026

Palatin Technologies, Inc. Common Stock (NASDAQ: PTN) Share Price, PTN Stock News, PTN Share Price & Updates - Kalkine

Aug 14, 2026

Palatin Technologies (PTN) gains 4.7% stake holder AuGC BioFund in 13G/A - Stock Titan

Aug 14, 2026

Aug 09, 2026